{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:45:08Z","timestamp":1785887108245,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA116201"],"award-info":[{"award-number":["P50 CA116201"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.annonc.2026.05.702","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:21:38Z","timestamp":1782314498000},"page":"873-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic"],"prefix":"10.1016","volume":"37","author":[{"given":"K.V.","family":"Giridhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4383-270X","authenticated-orcid":false,"given":"M.P.","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.annonc.2026.05.702_bib1","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"15","author":"Fisher","year":"1997","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.702_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9938","key":"10.1016\/j.annonc.2026.05.702_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.annonc.2026.05.702_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2026.05.702_bib5","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","volume":"394","author":"Loibl","year":"2026","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.annonc.2026.05.702_bib6","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"10437","key":"10.1016\/j.annonc.2026.05.702_bib7","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","volume":"403","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.annonc.2026.05.702_bib8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2026.05.702_bib9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2026.04.007","article-title":"Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+\/HER2\u2212 and ADAPTcycle trials (N = 7914)","volume":"37","author":"Gluz","year":"2026","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.05.702_bib10","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","article-title":"Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial","volume":"21","author":"Smith","year":"2020","journal-title":"Lancet Onco"},{"issue":"23","key":"10.1016\/j.annonc.2026.05.702_bib11","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.21.02759","article-title":"Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+\/HER2\u2212 early breast cancer","volume":"40","author":"Nitz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.702_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2025.01.004","article-title":"Expanding the role of CDK4\/6 inhibitors in early breast cancer: insights from the NATALEE trial","volume":"36","author":"Carausu","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.702_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.annonc.2025.10.012","article-title":"Long-term outcomes with adjuvant CDK4\/6 inhibitors: who benefits most?","volume":"37","author":"O\u2019Meara","year":"2026","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.05.702_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105858","article-title":"Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival","volume":"10","author":"Crown","year":"2025","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.702_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","article-title":"Overall survival with abemaciclib in early breast cancer","volume":"37","author":"Johnston","year":"2026","journal-title":"Ann Oncol"},{"issue":"10503","key":"10.1016\/j.annonc.2026.05.702_bib16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(25)01013-X","volume":"406","year":"2025","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.annonc.2026.05.702_bib17","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.702_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.702_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1245\/s10434-025-18307-4","article-title":"Neoadjuvant endocrine therapy use in estrogen receptor positive breast cancer: insights from practice shifts during the COVID-19 pandemic","volume":"33","author":"Douglas","year":"2026","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.702_bib20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-019-05397-4","article-title":"Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States","volume":"178","author":"Pariser","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.annonc.2026.05.702_bib21","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S1470-2045(20)30478-2","article-title":"Implementing preoperative endocrine therapy in breast cancer","volume":"21","author":"Mu\u00f1oz","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2026.05.702_bib22","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group","volume":"113","author":"Nielsen","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.702_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41379-018-0109-4","article-title":"An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer","volume":"32","author":"Rimm","year":"2019","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.annonc.2026.05.702_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/bjc.1991.147","article-title":"Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients","volume":"63","author":"Lien","year":"1991","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2026.05.702_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/17512433.2019.1610390","article-title":"Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen","volume":"12","author":"Sanchez-Spitman","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4_suppl","key":"10.1016\/j.annonc.2026.05.702_bib26","article-title":"Abstract PS5-12-16: a phase 2 trial of (Z)-endoxifen+ goserelin as neoadjuvant treatment for premenopausal women with ER+, HER2\u2212, breast cancer (EVANGELINE)","volume":"32","author":"Goetz","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"4_suppl","key":"10.1016\/j.annonc.2026.05.702_bib27","article-title":"Abstract PS3-07-10: low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot","volume":"32","author":"Giridhar","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.05.702_bib28","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41598-024-51723-2","article-title":"AI improves accuracy, agreement and efficiency of pathologists for Ki67 assessments in breast cancer","volume":"14","author":"Dy","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.annonc.2026.05.702_bib29","article-title":"Concordance of Oncotype DX Breast Recurrence Score assay results between paired core needle biopsy and surgical excision specimens in hormone receptor-positive, human epidermal growth factor receptor 2-negative, early-stage breast cancer","volume":"9","author":"Nassar","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.702_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.05.702_bib31","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/jmri.26770","article-title":"Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL","volume":"50","author":"Li","year":"2019","journal-title":"J Magn Reson Imaging"},{"issue":"15","key":"10.1016\/j.annonc.2026.05.702_bib32","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-22-0068","article-title":"Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for response to neoadjuvant endocrine therapy and longer-term breast cancer patient outcomes (Alliance Z1031)","volume":"28","author":"Suman","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.annonc.2026.05.702_bib33","doi-asserted-by":"crossref","DOI":"10.1172\/JCI188458","article-title":"CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer","volume":"136","author":"Napolitano","year":"2026","journal-title":"J Clin Invest"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426008859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426008859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:54:43Z","timestamp":1785884083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426008859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0923753426008859"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.702","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}